Interim results from ganetespib Phase 2 trial in NSCLC to be presented at 11th IASLC annual meeting

Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that Dr. Jonathan Goldman, M.D., Premiere Oncology will present interim results from a Phase 2 trial of ganetespib (formerly STA-9090) in non-small cell lung cancer (NSCLC) at the International Association for the Study of Lung Cancer (IASLC) 11^th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting on Saturday, February 26, 2011 at the Fairmont Miramar Hotel in Santa Monica, California.

Ganetespib is a best-in-class inhibitor of heat shock protein 90 (Hsp90) that is currently being studied in a broad range of Phase 2 trials and has demonstrated clinical activity as a monotherapy as well as a favorable safety profile.